Holen Sie sich die Stockscreener-App
1.72
1.15%
-0.02
Schlusskurs vom Vortag:
$1.74
Offen:
$1.75
24-Stunden-Volumen:
885.18K
Relative Volume:
0.57
Marktkapitalisierung:
$115.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-122.44M
KGV:
-0.7631
EPS:
-2.254
Netto-Cashflow:
$-103.79M
1W Leistung:
+4.88%
1M Leistung:
+9.55%
6M Leistung:
-78.95%
1J Leistung:
-47.72%
1-Tages-Spanne:
$1.695
$1.81
1-Wochen-Bereich:
$1.62
$1.82
52-Wochen-Spanne:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Firmenname
Engene Therapeutics Inc
Sektor
Branche
Telefon
(514) 332-4888
Adresse
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.72 | 115.22M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | WBB Securities | Buy |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-14 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-27 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-03-28 | Eingeleitet | UBS | Buy |
| 2024-03-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Engene Therapeutics Inc Aktie (ENGN) Neueste Nachrichten
Morgan Stanley Downgrades EnGene to Underweight From Equalweight - Moomoo
ENGN Downgraded by Morgan Stanley -- Rating Changed to Underweig - GuruFocus
EnGene Shares Fall After Morgan Stanley Downgrade - Moomoo
enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan
enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape - Streetwise Reports
EnGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says - marketscreener.com
Morgan Stanley Downgrades enGene to Underweight From Equalweight - marketscreener.com
Morgan Stanley cuts Engene stock rating on reduced sales outlook - Investing.com
Morgan Stanley cuts Engene stock rating on reduced sales outlook By Investing.com - Investing.com UK
enGene Therapeutics (ENGN) director awarded options for 31,000 shares - Stock Titan
enGene Therapeutics (ENGN) grants director 31,000 stock options - Stock Titan
enGene Therapeutics (ENGN) director receives 31,000 stock options at $1.75 strike - Stock Titan
[Form 4] enGene Therapeutics Inc. Insider Trading Activity - Stock Titan
enGene Therapeutics (ENGN) director awarded 31,000 stock options - Stock Titan
Director Michael Heffernan of enGene (ENGN) awarded options on 31,000 shares - Stock Titan
Lota S. Zoth granted 31,000 options at enGene Therapeutics (ENGN) - Stock Titan
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV) - The Globe and Mail
Guggenheim Maintains EnGene Therapeutics(ENGN.US) With Hold Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
EnGene slashes staff by 50% to preserve cash ahead of regulatory push - The Business Journals
ENGN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Engene stock price target on clinical setbacks - Investing.com
Layoff Tracker: Neumora, enGene cut staff in cost-saving initiatives - BioSpace
enGene (ENGN) Announces Workforce Reduction and Leadership Changes - GuruFocus
enGene Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
EnGene Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 - marketscreener.com
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene Therapeutics Inc. (ENGNW) Q2 2026 Quarterly Report: Financial Highlights, Risk Factors, and Forward-Looking Statements - Minichart
enGene Therapeutics (ENGN) Q2 2026 earnings summary - Quartr
enGene Therapeutics reports Q2 2026 financial results - grafa.com
enGene Reports Q2 2026 Results: 50% Workforce Reduction, BLA Initiation for Detalimogene in 2H 2026, $285M Cash Position, and NMIBC Clinical Updates 12 – Minichart - Minichart
enGene Restructures, Cuts Workforce to Advance Bladder Therapy - TipRanks
enGene Therapeutics Inc. Q3 2026: Net loss $30.2M, EPS ($0.43) — 10-Q Summary - TradingView
ENGN: Net loss increased, workforce halved, and liquidity remains strong for at least 12 months - TradingView
enGene Therapeutics (ENGN) posts $60M loss, cuts workforce by 50% - Stock Titan
enGene (NASDAQ: ENGN) slashes staff 50% as it advances detalimogene BLA - Stock Titan
Genetic medicines company enGene cuts half its staff to focus on FDA filing - Stock Titan
enGene Therapeutics Inc. (ENGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why is enGene Therapeutics stock falling Friday? - MSN
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
ENGN Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against enGene Therapeutics Inc. (ENGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
enGene Holdings Shareholders Approve Board and Auditor Slate - TipRanks
Shareholders at enGene (ENGN) 2026 meeting back directors and auditor - Stock Titan
Number of shareholders of enGene Therapeutics Inc. – BOATS:ENGN - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Finanzdaten der Engene Therapeutics Inc-Aktie (ENGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):